These findings further confirm the considerable heterogeneity of CD8+ T-cells in the breast tumor microenvironment and emphasize that several parameters should be considered in the study of CD8+ T-cells, including the type and even subtype of cancers, and the expression of immune checkpoint inhibitors or activation markers. The gene discussed is CD8A; the disease is breast neoplasm.